- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
February 26, 2021Personal Injury and Medical Malpractice Partners Named to Minnesota Lawyer’s Power 30 List
-
February 22, 2021Robins Kaplan Expands Health Care Litigation Group
-
February 1, 2021Meegan Hollywood Selected to Join American Antitrust Institute Advisory Board
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
March, 9, 2021The New Frontier of Software License Disputes
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
February 26, 2021Financial Daily Dose 2.26.2021 | Top Story: Rising Long-Term Bond Yields Blamed for Jumpy Markets
-
February 25, 2021Financial Daily Dose 2.25.2021 | Top Story: McKinsey Ousts Managing Partner on Heels of Opioid Settlement
-
February 24, 2021Financial Daily Dose 2.24.2021 | Top Story: Chair Powell Promises Continued Fed Support for US Economy
Robins Kaplan LLP Earns Trial Win for Client Amneal Pharmaceuticals LLC in Hatch-Waxman Lawsuit Over Blockbuster Kidney Disease Drug
August 2, 2018
Minneapolis—August 2, 2018—Robins Kaplan LLP® secured a ruling of non-infringement of a proposed ANDA product in a Hatch-Waxman trial over the blockbuster kidney disease drug Sensipar®. The ruling, following a four-day trial in Delaware federal court, is a victory for Robins Kaplan’s client, Amneal Pharmaceuticals LLC.
“This was a hard fought case that required creativity and persistence from our legal team and from our client Amneal, and great cooperation among the defendants,” said Jake Holdreith, partner at Robins Kaplan and lead trial counsel for Amneal. “We faced a tough and motivated opponent. We are fortunate to have a great partnership with our client and a highly skilled legal team that allowed this win for Amneal.”
Amgen Inc., the manufacturer of Sensipar, originally sued Amneal and more than 15 other generic drug manufacturers, seeking to prevent them from introducing generic versions of Sensipar, which can lower the amount of calcium in the blood and is used to treat kidney disease in adults. Amgen’s U.S. sales of Sensipar exceeded $1.3 billion in 2017 alone. Its patent over Sensipar’s active ingredient expired on March 8, 2018, but a separate Amgen formulation patent, at issue in this case, remains in effect until 2026.
The Robins Kaplan team representing Amneal led a defense group that dwindled to nine at the final pretrial conference, five at the start of trial, and four during post-trial briefing, with others choosing to settle Amgen’s claims against them. Amneal proceeded to trial, and Judge Mitchell S. Goldberg ruled that Amneal, along with two other generic drug makers, did not infringe Amgen’s U.S. Patent 9,375,405.
Robins Kaplan principal Oren Langer and associate Kelsey McElveen played critical roles at trial on behalf of Amneal. “The most important mission we have is getting the best possible result for our clients. We are thrilled to be able to deliver that to Amneal in this case,” added Oren Langer.
The case, Amgen Inc. v. Amneal Pharms. LLC, was heard before the United States District Court for the District of Delaware by the Hon. Mitchell S. Goldberg, a visiting judge from the Eastern District of Pennsylvania.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.